Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover
bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of
Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fasting
condition